Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu-PRRT plus capecitabine versus Lu-PRRT in FDG-positive GEP-NET (Lu-Ca-S)
2014-003067-38Phase 2Terminated
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Sep 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lutetium Lu 177 dotatate and capecitabine in gastroenteropancreatic neuroendocrine tumor (GEP-NET) (2 arms), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Primary endpoint: progression free survival. Started Sep 2018; status: terminated.
02
Drugs
lutetium Lu 177 dotatatecapecitabine
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on 2014-003067-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003067-38.